These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 7380485)

  • 1. Methods for the estimation of pyrazinamide and pyrazinoic acid in body fluids.
    Gurumurthy P; Nair NG; Sarma GR
    Indian J Med Res; 1980 Jan; 71():129-34. PubMed ID: 7380485
    [No Abstract]   [Full Text] [Related]  

  • 2. [Microdetermination of pyrazinamide and its metabolites (pyrazinoic acid, 5-hydroxypyrazinoic acid, 5-hydroxypyrazinamide and pyrazinuric acid) in plasma and urine with liquid chromatography].
    Lacroix C; Poncet P; Laine G; Guyonnaud C; Ray M; Menager S; Lafont O
    J Chromatogr; 1987 Nov; 422():217-25. PubMed ID: 3437007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Polarographic quantification of pyrazinamide and benemycin in biological fluids].
    Tsukanov IuV; Sushkin AG; Guzeeva SA
    Probl Tuberk; 1977 Jan; (1):71-5. PubMed ID: 834765
    [No Abstract]   [Full Text] [Related]  

  • 4. [Simultaneous microdetermination of pyrazinamide and pyrazinoic acid by liquid chromatography].
    Lacroix C; Langlois B; Ménager S; Lafont O
    Ann Biol Clin (Paris); 1987; 45(3):297-9. PubMed ID: 3662137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass fragmentographic determination of pyrazinamide and its metabolites in serum and urine.
    Roboz J; Suzuki R; Yü TF
    J Chromatogr; 1978 Jan; 147():337-47. PubMed ID: 621253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrazinamide and pyrazinoic acid pharmacokinetics in patients with chronic renal failure.
    Stamatakis G; Montes C; Trouvin JH; Farinotti R; Fessi H; Kenouch S; Méry JP
    Clin Nephrol; 1988 Oct; 30(4):230-4. PubMed ID: 3214968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPLC assay of pyrazinoic acid in human plasma in the presence of pyrazinamide and other antituberculosis drugs using an automatic sampler.
    Ratti B; Toselli A; Beretta E; Bernareggi A
    Farmaco Prat; 1982 Jul; 37(7):226-34. PubMed ID: 7128773
    [No Abstract]   [Full Text] [Related]  

  • 8. Rapid liquid chromatographic method for the estimation of isoniazid and pyrazinamide in plasma and urine.
    Gaitonde CD; Pathak PV
    J Chromatogr; 1990 Nov; 532(2):418-23. PubMed ID: 2084138
    [No Abstract]   [Full Text] [Related]  

  • 9. Study of the metabolism of pyrazinamide using a high-performance liquid chromatographic analysis of urine samples.
    Yamamoto T; Moriwaki Y; Takahashi S; Hada T; Higashino K
    Anal Biochem; 1987 Feb; 160(2):346-9. PubMed ID: 3578761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron enhances the antituberculous activity of pyrazinamide.
    Somoskovi A; Wade MM; Sun Z; Zhang Y
    J Antimicrob Chemother; 2004 Feb; 53(2):192-6. PubMed ID: 14729751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid.
    Zhang Y; Wade MM; Scorpio A; Zhang H; Sun Z
    J Antimicrob Chemother; 2003 Nov; 52(5):790-5. PubMed ID: 14563891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.
    Lacroix C; Tranvouez JL; Phan Hoang T; Duwoos H; Lafont O
    Arzneimittelforschung; 1990 Jan; 40(1):76-9. PubMed ID: 2340003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The absorption and excretion of pyrazinamide. I. Preliminary study in laboratory animals and in man.
    Stottmeier KD; Beam RE; Kubica GP
    Am Rev Respir Dis; 1968 Jul; 98(1):70-4. PubMed ID: 5657154
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects.
    Lacroix C; Hoang TP; Nouveau J; Guyonnaud C; Laine G; Duwoos H; Lafont O
    Eur J Clin Pharmacol; 1989; 36(4):395-400. PubMed ID: 2737233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetic study of pyrazinamide and pyrazinoic acid in subjects with normal renal function and patients with renal failure].
    Vayre P; Chambraud E; Fredj G; Thuillier A
    Therapie; 1989; 44(1):1-4. PubMed ID: 2734715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of pyrazinoic acid on the transport function of the peritoneum--experimental studies].
    Czyzewska K; Knapowski J
    Pol Tyg Lek; 1990 Apr 16-30; 45(16-18):343-5. PubMed ID: 2235723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of urinary pyrazinamide metabolites and their action on the renal excretion of xanthine and hypoxanthine in a xanthinuric patient.
    Auscher C; Pasquier C; Pehuet P; Delbarre F
    Biomedicine; 1978 May; 28(2):129-33. PubMed ID: 667278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the effects of concomitant caffeine administration on the metabolic disposition of pyrazinamide in rats.
    Mehmedagic A; Verite P; Menager S; Tharasse C; Chabenat C; Andre D; Lafont O
    Biopharm Drug Dispos; 2002 Jul; 23(5):191-5. PubMed ID: 12116050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrazinoic acid decreases peritoneal transfer rates.
    Grzegorzewska AE; Czyzewska K; Szary B
    Adv Perit Dial; 1995; 11():33-5. PubMed ID: 8534732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of pyrazinamide in human by high performance liquid chromatography.
    Revankar SN; Desai ND; Vaidya AB; Bhatt AD; Anjaneyulu B
    J Postgrad Med; 1994; 40(1):7-9. PubMed ID: 8568720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.